The first FDA-approved drug for frostbite can save limbs from amputation, and researchers are working on “coldscreen” preventatives.

字号 + –

27 1月 2025

1
2
3
4
5

Author : 伤口世界

The first FDA-approved drug for frostbite can save limbs from amputation, and researchers are working on “coldscreen” preventatives.

This article is excerpted from the ACS Cent. Sci. 2024, 10, 1976−1979 by Wound World.

397 Views

伤口世界

电子邮件地址 michael.kung@139.com

Latest from 伤口世界

Human trials exploring anti-aging medicines
Contrasting somatic mutation patterns in aging human neurons and oligodendrocytes
Contrasting somatic mutation patterns in aging human neurons and oligodendrocytes
A Comprehensive Review of Stem Cell Conditioned Media Role for Anti-Aging on Skin
Oral Administration of Nacre Extract from Pearl Oyster Shells Has Anti-Aging Effects on Skin and Muscle, and Extends the Lifespan in SAMP8 Mice

K2 Content

Human trials exploring anti-aging medicines 2025-06-18 00:00

Leonard Guarente,1,2, * David A. Sinclair,2,3 and Guido Kroemer2,4,5,6, *

1 Department of Biology, Massachusetts Institute for Technology, Cambridge, MA 02139

2 Academy for Healthspan and Lifespan Research (AHLR), New York, NY, USA

3 Blavatnik Institute, Genetics Department, Harvard Medical School, Boston, MA 02115, USA

4 Centre de Recherche des Cordeliers, Equipe labellise´ e par la Ligue contre le cancer, Universite´ Paris Cite´ , Sorbonne Universite´ , Inserm U1138, Institut Universitaire de France, Paris, France

5 Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France

6 Institut du Cancer Paris CARPEM, Department of Biology, Hoˆ pital Europe´ en Georges Pompidou, AP-HP, Paris, France

*Correspondence: leng@mit.edu (L.G.), kroemer@orange.fr (G.K.)

https://doi.org/10.1016/j.cmet.2023.12.007

SUMMARY

Here, we summarize the current knowledge on eight promising drugs and natural compounds that have been tested in the clinic: metformin, NAD+ precursors, glucagon-like peptide-1 receptor agonists, TORC1 inhibitors, spermidine, senolytics, probiotics, and anti-inflammatories. Multiple clinical trials have commenced to evaluate the efficacy of such agents against age-associated diseases including diabetes, cardiovascular disease, cancer, and neurodegenerative diseases. There are reasonable expectations that drugs able to decelerate or reverse aging processes will also exert broad disease-preventing or -attenuating effects. Hence, the outcome of past, ongoing, and future disease-specific trials may pave the way to the development of new anti-aging medicines. Drugs approved for specific disease indications may subsequently be repurposed for the treatment of organism-wide aging consequences.
Contrasting somatic mutation patterns in aging human neurons and oligodendrocytes 2025-06-17 00:00

Javier Ganz,1,2,3,8,9 Lovelace J. Luquette,4,8 Sara Bizzotto,1,2,3,5,8 Michael B. Miller,1,3,6 Zinan Zhou,1,2,3 Craig L. Bohrson,4

Hu Jin,4 Antuan V. Tran,4 Vinayak V. Viswanadham,4 Gannon McDonough,6 Katherine Brown,6 Yasmine Chahine,1

Brian Chhouk,1 Alon Galor,4 Peter J. Park,4,7,* and Christopher A. Walsh1,2,3,10,*

1 Division of Genetics and Genomics, Manton Center for Orphan Disease Research, Department of Pediatrics, and Howard Hughes Medical Institute, Boston Childrens Hospital, Boston, MA 02115, USA

2 Departments of Pediatrics and Neurology, Harvard Medical School, Boston, MA 02115, USA

3 Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA

4 Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA

5 Sorbonne Universite´ , Institut du Cerveau (Paris Brain Institute) ICM, Inserm, CNRS, Hoˆ pital de la Pitie´ Salpeˆ trie`re, 75013 Paris, France

6 Department of Pathology, Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02115, USA

7 Division of Genetics, Brigham and Womens Hospital, Boston, MA 02115, USA

8 These authors contributed equally

9 Present address: Merck Research Laboratories, Cambridge, MA 02142, USA

10 Lead contact

*Correspondence: peter_park@hms.harvard.edu (P.J.P.), christopher.walsh@childrens.harvard.edu (C.A.W.)

https://doi.org/10.1016/j.cell.2024.02.025

SUMMARY

Characterizing somatic mutations in the brain is important for disentangling the complex mechanisms of aging, yet little is known about mutational patterns in different brain cell types. Here, we performed wholegenome sequencing (WGS) of 86 single oligodendrocytes, 20 mixed glia, and 56 single neurons from neurotypical individuals spanning 0.4–104 years of age and identified >92,000 somatic single-nucleotide variants (sSNVs) and small insertions/deletions (indels). Although both cell types accumulate somatic mutations linearly with age, oligodendrocytes accumulated sSNVs 81% faster than neurons and indels 28% slower than neurons. Correlation of mutations with single-nucleus RNA profiles and chromatin accessibility from the same brains revealed that oligodendrocyte mutations are enriched in inactive genomic regions and are distributed across the genome similarly to mutations in brain cancers. In contrast, neuronal mutations are enriched in open, transcriptionally active chromatin. These stark differences suggest an assortment of active mutagenic processes in oligodendrocytes and neurons.
Contrasting somatic mutation patterns in aging human neurons and oligodendrocytes 2025-06-16 00:00

an Yang1 Xinyuan Zhang2 Hua Wang1 Miao Guo1 Jinlong Zhang1 Xuejiao Feng3 Jiayi Yu3 Jiahui Yang3 Jinjin Zhu4 Yiyu Wang3

1 Research & Development Center, Mageline Biology Tech Co., Ltd, Wuhan, Hubei, China

2 Shanghai Skinshield Clinical Testing and Technological Research Ltd., Shanghai, China

3 Department of Dermatology, Air Force Medical Center, PLA, Beijing, China

4 Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, China

Correspondence

Jinjin Zhu, Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (HUST), Wuhan, 430022, China.

Email: zhujinjinhust@foxmail.com

Yiyu Wang, Department of Dermatology, Air Force Medical Center, PLA, Beijing, China.

Email: wangyiyuderm@163.com

Abstract

Background: The delicate periorbital region is susceptible to skin dehydration, wrinkles, and loss of elasticity. Thus, targeted and effective anti-aging interventions are necessary for the periorbital area.

Aim: To evaluate the efficacy and safety of a new anti-aging eye cream formulated with the active complex (Yeast/rice fermentation filtrate, N-acetylneuraminic acid, palmityl tripeptide-1, and palmitoyl tetrapeptide-7).

Methods: The cell viability and expressions of key extracellular matrix (ECM) components of the active complex were evaluated using a human skin fibroblast model. In the 12-week clinical trial, skin hydration, elasticity, facial photographs, and collagen density following eye cream application were assessed using Corneometer, Cutometer, VISIA, and ultrasound device, respectively. Dermatologists and participants evaluated clinical efficacy and safety at baseline, and after 4, 8, and 12 weeks.

Results: PCR and immunofluorescent analyses revealed that the active complex significantly stimulated fibroblast proliferation (p < 0.05) and markedly promote the synthesis of collagen and elastin. Clinical findings exhibited a substantial enhancement in skin hydration (28.12%), elasticity (18.81%), and collagen production (54.99%) following 12 weeks of eye cream application. Dermatological evaluations and participants’ assessments reported a significant improvement in skin moisture, roughness, elasticity, as well as fine lines and wrinkles by week 8.

Conclusion: The new anti-aging eye cream, enriched with the active complex, demonstrates comprehensive rejuvenating effects, effectively addressing aging concerns in the periorbital area, coupled with a high safety profile.

KEYWORDS

anti-aging, collagen, elastin, extracellular matrix, eye cream, wrinkle

Custom Mod Mega1

主任医师、教授、博导，南方医科大学第三附属医院（广东省骨科医院）院长

The first FDA-approved drug for frostbite can save limbs from amputation, and researchers are working on “coldscreen” preventatives.

伤口世界

Latest from 伤口世界

学术会议

伤口世界提示

Custom Mod Mega1

主任医师、教授、博导，南方医科大学第三附属医院（广东省骨科医院）院长

The first FDA-approved drug for frostbite can save limbs from amputation, and researchers are working on “coldscreen” preventatives.

伤口世界

Latest from 伤口世界

消息订阅

学术会议

伤口世界提示